Literature DB >> 27129110

Correlation of the patient's reported outcome Inflammatory-RODS with an objective metric in immune-mediated neuropathies.

T H P Draak1, K C Gorson2, E K Vanhoutte3, S I van Nes4, P A van Doorn5, D R Cornblath6, L H van den Berg7, C G Faber1, I S J Merkies1,8.   

Abstract

BACKGROUND AND
PURPOSE: There is increasing interest in using patient-reported outcome measures (PROMs) in clinical studies to capture individual changes over time. However, PROMs have also been criticized because they are entirely subjective. Our objective was to examine the relationship between a subjective PROM and an objective outcome tool in patients with Guillain-Barré syndrome (GBS), chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and gammopathy-related polyneuropathy (MGUSP).
METHODS: The Inflammatory Rasch-built Overall Disability Scale (I-RODS©, a multi-item scale that examines functionality) was completed by 137 patients with newly diagnosed (or relapsing) GBS (55), CIDP (59) and MGUSP (23) who were serially examined (GBS/CIDP, T0/T1/T3/T6/T12 months; MGUSP, T0/T3/T12). Possible association between the I-RODS findings and the vigorimeter scores, an objective linear instrument to assess grip strength, was examined.
RESULTS: A significant correlating trend was found between the I-RODS and grip strength scores for the overall group and in each illness, independently.
CONCLUSION: The objectivity of patients' subjective report on their functional state based on a strong correlation between the I-RODS and grip strength in patients with GBS, CIDP and MGUSP has been demonstrated. These findings provide further support to use the I-RODS and grip strength in future clinical studies in these conditions.
© 2016 EAN.

Entities:  

Keywords:  Guillain−Barré syndrome; IgM-monoclonal gammopathy of undetermined significance related polyneuropathy; chronic inflammatory demyelinating polyneuropathy; patient reported outcome measure; peripheral neuropathy

Mesh:

Year:  2016        PMID: 27129110     DOI: 10.1111/ene.13025

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  5 in total

Review 1.  Individualized immunoglobulin therapy in chronic immune-mediated peripheral neuropathies.

Authors:  Jeffrey A Allen; Melvin Berger; Luis Querol; Krista Kuitwaard; Robert D Hadden
Journal:  J Peripher Nerv Syst       Date:  2018-04-19       Impact factor: 3.494

2.  Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in chronic inflammatory demyelinating polyradiculoneuropathy: protocol of an international, randomised, double-blind, placebo-controlled trial (OPTIC).

Authors:  S R M Bus; L Zambreanu; A Abbas; Y A Rajabally; R D M Hadden; R J de Haan; C A J M de Borgie; M P Lunn; I N van Schaik; F Eftimov
Journal:  Trials       Date:  2021-02-19       Impact factor: 2.279

3.  Withdrawal of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Max E Adrichem; Ilse M Lucke; Alexander F J E Vrancken; H Stephan Goedee; Luuk Wieske; Marcel G W Dijkgraaf; Nicol C Voermans; Nicolette C Notermans; Catharina G Faber; Leo H Visser; Krista Kuitwaard; Pieter A van Doorn; Ingemar S J Merkies; Rob J de Haan; Ivo N van Schaik; Filip Eftimov
Journal:  Brain       Date:  2022-06-03       Impact factor: 15.255

4.  Analysis of relapse by inflammatory Rasch-built overall disability scale status in the PATH study of subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy.

Authors:  Ingemar S J Merkies; Ivo N van Schaik; Vera Bril; Hans-Peter Hartung; Richard A Lewis; Gen Sobue; John-Philip Lawo; Orell Mielke; David R Cornblath
Journal:  J Peripher Nerv Syst       Date:  2022-03-15       Impact factor: 5.188

Review 5.  Management challenges for chronic dysimmune neuropathies during the COVID-19 pandemic.

Authors:  Yusuf A Rajabally; H Stephan Goedee; Shahram Attarian; Hans-Peter Hartung
Journal:  Muscle Nerve       Date:  2020-04-24       Impact factor: 3.852

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.